Preclinical studies in FGFR2 driven cholangiocarcinoma and breast cancer indicate that FGFR inhibitors can down regulate RAD51 and sensitise tumours to platinum salts or to poly ADP ribose polymerase inhibitors [58,59]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.